Isoacteoside, a dihydroxyphenylethyl glycoside, exhibits anti-inflammatory effects through blocking toll-like receptor 4 dimerization.

Hongwei GaoYankun CuiNaixin KangXin LiuYanli LiuYue ZouZiyu ZhangXiaoran LiShilin YangJi LiChunming WangQiong-Ming XuXiuping Chen

Published in: British journal of pharmacology (2017)

Isoacteoside blocked TLR4 dimerization, which activates the MyD88-TAK1-NF-κB/MAPK signalling cascades and TRIF pathway. Our data indicate that isoacteoside is a potential lead compound for the treatment of inflammatory diseases.

Keyphrases

toll like receptor
nuclear factor
inflammatory response
signaling pathway
oxidative stress
immune response
lps induced
pi k akt
electronic health record
big data
cell proliferation
risk assessment
machine learning
human health
combination therapy
climate change